Companies
Fidia Farmaceutici
Italian Fidia won FDA approval for HYMOVIS ONE, a single-injection hyaluronan therapy for knee osteoarthritis launched at AAOS 2026, and runs the established Hyalgan viscosupplementation line, while EU R&D develops HA–recombinant-collagen combination implants for tissue regeneration.
- Country
- Italy
OA viscosupplementation
HYMOVIS ONE FDA approved
eu
Coverage
| CN | EU | US | |
|---|---|---|---|
| specialty-fine-chem | ✓ | ✓ | ✓ |
Regulatorsfdaemanmpa
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Revenue | €538.3 million (2025-12-31) | fidiapharma.us · corriere.it · fidiapharma.it |
| Headcount | 1,708 employees (2025-12-31) | fidiapharma.us · corriere.it · fidiapharma.it |
| Regulatory approval | FDA premarket approval (PMA) for HYMOVIS ONE (2025-04-09) | fidiapharma.us · fidiapharma.com |
| Production site | Abano Terme (Padua), Noto (Syracuse), Paderno Dugnano (Milan), and Monte Giberto (Fermo) | fidiapharma.com |
| Capacity | Inaugurated a new biological medicines production unit at Abano Terme headquarters to expand capacity (2025-06-01) | fidiapharma.us · fidiapharma.it |
| Certification | ISO 9001, ISO 13485, ISO 14001, ISO 22716, and GMP certifications across various production sites (2024-12-31) | fidiapharma.com |
Independent sources: corriere.it · fidiapharma.com · fidiapharma.it · fidiapharma.us
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| Biosynthetic hyaluronic acid | specialty-fine-chem | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.